The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Influenza and antiviral resistance: an overview
Open accessAbstract
Influenza affects approximately 1 billion individuals each year resulting in between 290,000 and 650,000 deaths. Young children and immunocompromised individuals are at a particularly high risk of severe illness attributable to influenza and these are also the groups of individuals in which reduced susceptibility to neuraminidase inhibitors is most frequently seen. High levels of resistance emerged with previous adamantane therapy for influenza A and despite no longer being used to treat influenza and therefore lack of selection pressure, high levels of adamantane resistance continue to persist in currently circulating influenza A strains. Resistance to neuraminidase inhibitors has remained at low levels to date and the majority of resistance is seen in influenza A H1N1 pdm09 infected immunocompromised individuals receiving oseltamivir but is also seen less frequently with influenza A H3N2 and B. Rarely, resistance is also seen in the immunocompetent. There is evidence to suggest that these resistant strains (particularly H1N1 pdm09) are able to maintain their replicative fitness and transmissibility, although there is no clear evidence that being infected with a resistant strain is associated with a worse clinical outcome. Should neuraminidase inhibitor resistance become more problematic in the future, there are a small number of alternative novel agents within the anti-influenza armoury with different mechanisms of action to neuraminidase inhibitors and therefore potentially effective against neuraminidase inhibitor resistant strains. Limited data from use of novel agents such as baloxavir marboxil and favipiravir, does however show that resistance variants can also emerge in the presence of these drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Emergence and pandemic potential of swine-origin H1N1 influenza virus
Neumann, G., Noda, T., & Kawaoka, Y. (2009) · Nature · doi:10.1038/nature08157 · Cited by 1,561
Favipiravir (T-705), a novel viral RNA polymerase inhibitor
Furuta, Y., Gowen, B. B., Takahashi, K., Shiraki, K., Smee, D. F., & Barnard, D. L. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.09.015 · Cited by 1,072
Treanor, J. J., Hayden, F. G., Vrooman, P. S., Barbarash, R., Bettis, R., Riff, D., Singh, S., Kinnersley, N., Ward, P., Mills, R. G., et al. (2000) · JAMA · doi:10.1001/jama.283.8.1016 · Cited by 1,014
The molecular basis of the specific anti-influenza action of amantadine.
Hay, A. J., Wolstenholme, A. J., Skehel, J. J., & Smith, M. H. (1985) · The EMBO Journal · doi:10.1002/j.1460-2075.1985.tb04038.x · Cited by 847
Initial Genetic Characterization of the 1918 “Spanish” Influenza Virus
Taubenberger, J. K., Reid, A. H., Krafft, A. E., Bijwaard, K. E., & Fanning, T. G. (1997) · Science · doi:10.1126/science.275.5307.1793 · Cited by 715
Permissive Secondary Mutations Enable the Evolution of Influenza Oseltamivir Resistance
Bloom, J. D., Gong, L. I., & Baltimore, D. (2010) · Science · doi:10.1126/science.1187816 · Cited by 649
Mechanism of Action of T-705 against Influenza Virus
Furuta, Y., Takahashi, K., Kuno-Maekawa, M., Sangawa, H., Uehara, S., Kozaki, K., Nomura, N., Egawa, H., & Shiraki, K. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.3.981-986.2005 · Cited by 546
Quantitative and sensitive detection of rare mutations using droplet-based microfluidics
Pekin, D., Skhiri, Y., Baret, J.-C., Le Corre, D., Mazutis, L., Ben Salem, C., Millot, F., El Harrak, A., Hutchison, J. B., Larson, J. W., et al. (2011) · Lab on a Chip · doi:10.1039/c1lc20128j · Cited by 540
Infectious virus in exhaled breath of symptomatic seasonal influenza cases from a college community
Yan, J., Grantham, M., Pantelic, J., Bueno de Mesquita, P. J., Albert, B., Liu, F., Ehrman, S., Milton, D. K., EMIT Consortium, Adamson, W., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1716561115 · Cited by 534 · cited 1×
“Possibly by airborne transmission via small aerosols (< 5 μm) generated from breathing/talking (and can remain suspended in the air for minutes to hours) [2]; however, there is limited data to suggest that infectious particles can be transmitted over long distances (and special air handling and ventilation systems are…”
BackgroundInfections With Oseltamivir-Resistant Influenza A(H1N1) Virus in the United States
Dharan, N. J. (2009) · JAMA · doi:10.1001/jama.2009.294 · Cited by 527
Drug resistance in influenza A virus: the epidemiology and management
Hussain, M., Galvin, H., Haw, T. Y., Nutsford, A., & Husain, M. (2017) · Infection and Drug Resistance · doi:10.2147/idr.s105473 · Cited by 439
Osterhaus, A. D. M. E., Rimmelzwaan, G. F., Martina, B. E. E., Bestebroer, T. M., & Fouchier, R. A. M. (2000) · Science · doi:10.1126/science.288.5468.1051 · Cited by 415
Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance
McKimm‐Breschkin, J. L. (2013) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.12047 · Cited by 390
Ives, J. A. L., Carr, J. A., Mendel, D. B., Tai, C. Y., Lambkin, R., Kelly, L., Oxford, J. S., Hayden, F. G., & Roberts, N. A. (2002) · Antiviral Research · doi:10.1016/s0166-3542(02)00053-0 · Cited by 379
Oseltamivir Resistance — Disabling Our Influenza Defenses
Moscona, A. (2005) · New England Journal of Medicine · doi:10.1056/nejmp058291 · Cited by 332
The mechanism of resistance to favipiravir in influenza
Goldhill, D. H., te Velthuis, A. J. W., Fletcher, R. A., Langat, P., Zambon, M., Lackenby, A., & Barclay, W. S. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1811345115 · Cited by 298
Comparison of the Mutation Rates of Human Influenza A and B Viruses
Nobusawa, E., & Sato, K. (2006) · Journal of Virology · doi:10.1128/jvi.80.7.3675-3678.2006 · Cited by 293
Hurt, A. C., Besselaar, T. G., Daniels, R. S., Ermetal, B., Fry, A., Gubareva, L., Huang, W., Lackenby, A., Lee, R. T. C., Lo, J., et al. (2016) · Antiviral Research · doi:10.1016/j.antiviral.2016.06.001 · Cited by 270
Recovery of Drug‐Resistant Influenza Virus from Immunocompromised Patients: A Case Series
Ison, M. G., Gubareva, L. V., Atmar, R. L., Treanor, J., & Hayden, F. G. (2006) · The Journal of Infectious Diseases · doi:10.1086/500465 · Cited by 261
Hurt, A. C., Chotpitayasunondh, T., Cox, N. J., Daniels, R., Fry, A. M., Gubareva, L. V., Hayden, F. G., Hui, D. S., Hungnes, O., Lackenby, A., et al. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70318-8 · Cited by 228
Susceptibilities of Antiviral-Resistant Influenza Viruses to Novel Neuraminidase Inhibitors
Mishin, V. P., Hayden, F. G., & Gubareva, L. V. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.11.4515-4520.2005 · Cited by 216
Baloxavir: First Global Approval
Heo, Y. (2018) · Drugs · doi:10.1007/s40265-018-0899-1 · Cited by 211
Uehara, T., Hayden, F. G., Kawaguchi, K., Omoto, S., Hurt, A. C., De Jong, M. D., Hirotsu, N., Sugaya, N., Lee, N., Baba, K., et al. (2019) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiz244 · Cited by 191
Systematic review of influenza resistance to the neuraminidase inhibitors
Thorlund, K., Awad, T., Boivin, G., & Thabane, L. (2011) · BMC Infectious Diseases · doi:10.1186/1471-2334-11-134 · Cited by 189
Clinical Implications of Antiviral Resistance in Influenza
Li, T., Chan, M., & Lee, N. (2015) · Viruses · doi:10.3390/v7092850 · Cited by 175
Mutations of neuraminidase implicated in neuraminidase inhibitors resistance
Ferraris, O., & Lina, B. (2008) · Journal of Clinical Virology · doi:10.1016/j.jcv.2007.10.020 · Cited by 171
Takashita, E., Meijer, A., Lackenby, A., Gubareva, L., Rebelo-de-Andrade, H., Besselaar, T., Fry, A., Gregory, V., Leang, S.-K., Huang, W., et al. (2015) · Antiviral Research · doi:10.1016/j.antiviral.2015.02.003 · Cited by 158
Viral determinants of influenza A virus host range
Cauldwell, A. V., Long, J. S., Moncorgé, O., & Barclay, W. (2014) · Journal of General Virology · doi:10.1099/vir.0.062836-0 · Cited by 150
Lackenby, A., Besselaar, T. G., Daniels, R. S., Fry, A. M., Gregory, V., Gubareva, L. V., Huang, W., Hurt, A. C., Leang, S.-K., Lee, R. T. C., et al. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2018.07.001 · Cited by 139
Duval, X., van der Werf, S., Blanchon, T., Mosnier, A., Bouscambert‐Duchamp, M., Tibi, A., Enouf, V., Charlois-Ou, C., Vincent, C., Andréoletti, L., et al. (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000362 · Cited by 136
The potential impact of neuraminidase inhibitor resistant influenza
Lackenby, A., Thompson, C., & Democratis, J. (2008) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e3283199797 · Cited by 124
Ng, S., Cowling, B. J., Fang, V. J., Chan, K. H., Ip, D., Cheng, C. K. Y., Uyeki, T. M., Houck, P. M., Peiris, M. J. S., & Leung, G. M. (2010) · Clinical Infectious Diseases · doi:10.1086/650458 · Cited by 121
Evaluation of Intravenous Peramivir for Treatment of Influenza in Hospitalized Patients
de Jong, M. D., Ison, M. G., Monto, A. S., Metev, H., Clark, C. L., O’Neil, B. J., Elder, J., McCullough, A. J., Collis, P., & Sheridan, W. P. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu632 · Cited by 120
Resistance to anti-influenza drugs: adamantanes and neuraminidase inhibitors
Hurt, A. C., Ho, H.-T., & Barr, I. (2006) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.4.5.795 · Cited by 107
Structural and Functional Basis of Resistance to Neuraminidase Inhibitors of Influenza B Viruses
Oakley, A. J., Barrett, S., Peat, T. S., Newman, J. M., Streltsov, V. A., Waddington, L. J., Saito, T., Tashiro, M., & McKimm‐Breschkin, J. L. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100621s · Cited by 93
Clinical use of approved influenza antivirals: therapy and prophylaxis
Ison, M. G. (2012) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.12046 · Cited by 83
Kim, W., Suh, G. Y., Huh, J. W., Kim, S.-H., Kim, M.-J., Kim, Y. S., Kim, H.-R., Ryu, Y. J., Han, M. S., Ko, Y. G., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05529-11 · Cited by 65
Whale, A. S., Bushell, C. A., Grant, P. R., Cowen, S., Gutiérrez‐Aguirre, I., O’Sullivan, D. M., Žel, J., Milavec, M., Foy, C. A., Nastouli, E., et al. (2015) · Journal of Clinical Microbiology · doi:10.1128/jcm.02611-15 · Cited by 65
Prachanronarong, K., Canale, A. S., Liu, P., Somasundaran, M., Hou, S., Poh, Y.-P., Han, T. K., Zhu, Q. K., Renzette, N., Zeldovich, K. B., et al. (2018) · Journal of Virology · doi:10.1128/jvi.01639-18 · Cited by 53
Petersen, E., Keld, D. B., Ellermann‐Eriksen, S., Gubbels, S., Ilkjær, S., Jensen‐Fangel, S., & Lindskov, C. (2011) · Scandinavian Journal of Infectious Diseases · doi:10.3109/00365548.2011.556144 · Cited by 41
Wu, Y., Gao, F., Qi, J., Bi, Y., Fu, L., Mohan, S., Chen, Y., Li, X., Pinto, B. M., Vavricka, C. J., et al. (2016) · Journal of Virology · doi:10.1128/jvi.01703-16 · Cited by 30
Pichon, M., Gaymard, A., Josset, L., Valette, M., Millat, G., Lina, B., & Escuret, V. (2017) · Antiviral Research · doi:10.1016/j.antiviral.2017.07.021 · Cited by 27
Dixit, R., Khandaker, G., Hay, P. D., McPhie, K. A., Taylor, J., Rashid, H., Heron, L. G., Dwyer, D. E., & Booy, R. (2014) · Antiviral Therapy · doi:10.3851/imp2807 · Cited by 16
Pizzorno, A., Abed, Y., Rhéaume, C., & Boivin, G. (2014) · Antiviral Research · doi:10.1016/j.antiviral.2014.02.017 · Cited by 14
Yip, J. L. Y., Kapadia, S., Ahmed, A., & Millership, S. E. (2018) · Public Health · doi:10.1016/j.puhe.2018.05.028 · Cited by 14
Cited by
A brief review of influenza virus infection
Javanian, M., Barary, M., Ghebrehewet, S., Koppolu, V., Vasigala, V., & Ebrahimpour, S. (2021) · Journal of Medical Virology · doi:10.1002/jmv.26990 · Cited by 458
Synergistic Effects Between Metal Nanoparticles and Commercial Antimicrobial Agents: A Review
Ribeiro, A. I., Dias, A. M., & Zille, A. (2022) · ACS Applied Nano Materials · doi:10.1021/acsanm.1c03891 · Cited by 276
Metadata
- Authors
- Lampejo, T.
- Venue
- European Journal of Clinical Microbiology & Infectious Diseases
- Published
- 2020-02-13
- Volume
- 39
- Issue
- 7
- Pages
- 1201-1208
- ISSN
- 0934-9723 (ISSN-L)
- 1435-4373
- OpenAlex
- W3006274289
- Cited by
- 342
- References
- 45
- FWCI
- 29.03
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.